Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.43 |
| ▸ | HRH1 | P35367 | 9/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3683201 | 0.80 | HTR2A (0.33) | HTR2AHRH1HTR2CSLC6A2DRD2 | |
| SCHEMBL7465941 | 0.78 | PNMT (0.35) | HTR2APNMT | |
| SCHEMBL4653293 | 0.72 | — | — | |
| SCHEMBL7628272 | 0.70 | GABRA1 (0.40) | HTR2AHTR2CPNMTDRD2 | |
| SCHEMBL12935970 | 0.69 | PNMT (0.33) | PNMT | |
| SCHEMBL4651927 | 0.69 | CYP1A2 (0.33) | — | |
| SCHEMBL5953538 | 0.68 | HTR2A (0.42) | HTR2AHRH1PNMTDRD2 | |
| SCHEMBL29262894 | 0.68 | HTR2A (0.43) | HTR2AHRH1HTR2C | |
| SCHEMBL3683410 | 0.68 | HTR2A (0.35) | HTR2A | |
| SCHEMBL12935958 | 0.68 | METAP1 (0.49) | HTR2AHRH1HTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569532-B2 | Catalysts | BOREALIS TECHNOLOGY OY (FI) | 2013-10-29 | — | — | US | disclosed |
| US-20120252993-A1 | CATALYSTS | BOREALIS TECHNOLOGY OY (FI) | 2012-10-04 | — | — | US | disclosed |
| US-20100305286-A1 | CATALYSTS | BOREALIS TECHNOLOGY OY (FI) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252993-A1 | CATALYSTS | CYP4F11, COXFA4, CYP2F1 | HTR2A 4526/4885HRH1 3553/4885HTR2C 4081/4885 |
| US-20100305286-A1 | CATALYSTS | H1-2, CCNL2, H1-3 | HTR2A 1940/4885HRH1 724/4885HTR2C 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.